SCHEMBL5855152

SCHEMBL5855152

COC(=O)c1cccc(N2CCCC2=O)c1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 4/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RAB9A P51151 2/20 0.40
MYC P01106 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27892679 0.86 APOBEC3A (0.55) APOBEC3AAPOBEC3GKMT2AMEN1GAA
SCHEMBL5853684 0.83 ALDH1A1 (0.51) APOBEC3AAPOBEC3GKMT2AMEN1GAA
SCHEMBL5219497 0.82 MEN1 (0.43) APOBEC3AAPOBEC3GKMT2AMEN1GAA
SCHEMBL5219064 0.81 HSD17B10 (0.42) KMT2AMEN1GAASMN1; SMN2KDM4E
SCHEMBL5851474 0.81 SMN1; SMN2 (0.42) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL5216170 0.80 HSD17B10 (0.41) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL5216506 0.79 GFER (0.42) APOBEC3AAPOBEC3GKMT2AMEN1GAA
SCHEMBL5853141 0.78 CFTR (0.41) SMN1; SMN2KDM4EHPGDCYP1A2CYP3A4
SCHEMBL5222867 0.77 HSD17B10 (0.36) KMT2AMEN1GAASMN1; SMN2ALDH1A1
SCHEMBL5222872 0.77 HSD17B10 (0.36) KMT2AMEN1GAASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6992103-B2 Benzamide derivatives, processes for their preparation, and their pharmaceutical use SMITHKLINE BEECHAM P.L.C. (GB) 2006-01-31 US disclosed
US-20050085520-A1 Benzamide derivatives, processes for their preparation, and their pharmaceutical use SMITHKLINE BEECHAM P.L.C. (GB) 2005-04-21 US disclosed
EP-1448520-A1 BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE SMITHKLINE BEECHAM PLC (GB) 2004-08-25 EP disclosed
WO-2003045913-A1 BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE SMITHKLINE BEECHAM P.L.C. (GB) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050085520-A1 Benzamide derivatives, processes for their preparation, and their pharmaceutical use BACE2, PSEN2, BACE1 APOBEC3A 3939/4885APOBEC3G 3615/4885KMT2A 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.